Soligenix, INC 8-K filings

Soligenix, Inc. has filed a prospectus supplement to increase its existing 'at-the-market' equity offering program by an additional $2.5 million.

Soligenix, Inc. has terminated its HyBryte development program following a failed clinical trial and received a Nasdaq deficiency notice regarding its share price.

Soligenix, Inc. has filed a prospectus supplement to increase its existing at-the-market equity offering program by an additional $2.96 million.

Soligenix, Inc. announced its Phase 3 FLASH2 trial for HyBryte in cutaneous T-cell lymphoma was recommended to halt for futility, prompting a strategic review.

Soligenix, Inc. has entered into an At Market Issuance Sales Agreement with Rodman & Renshaw, LLC to potentially sell up to $3.45 million of common stock.

Soligenix, Inc. announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement, resolving a previously disclosed listing issue.

Soligenix, Inc. closed a $7.5 million public offering of common stock and warrants, extending its cash runway through the end of 2026.

Soligenix, Inc. announced that the FDA granted orphan drug designation to dusquetide (SGX945) for Behcet's Disease, providing seven years of market exclusivity upon approval.

Soligenix, Inc. received a notice from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement, potentially leading to delisting.

Soligenix, Inc. announced positive Phase 2a proof of concept study results for SGX945 (dusquetide) in treating Behet's Disease, showing biological efficacy and favorable comparison to apremilast.

Soligenix, Inc. announced that its stockholders approved the 2025 Equity Incentive Plan, re-elected all five director nominees, and ratified the appointment of Cherry Bekaert, LLP as auditors at the recent annual meeting.

Soligenix, Inc. amended its bylaws on March 25, 2025, to reduce the quorum required for stockholder meetings from a majority to one-third of voting power.

Soligenix, Inc. announces the full repayment and termination of its loan and security agreement with Pontifax Medison Finance, eliminating all related liens and security interests.

Soligenix has amended its loan agreement with Pontifax to allow for debt repayment via stock conversion at a reduced price, potentially extending the company's cash runway.

Soligenix, Inc. has entered into an agreement to sell up to $5.8 million of its common stock through an at-the-market offering with A.G.P./Alliance Global Partners.

Soligenix, Inc. has successfully regained compliance with Nasdaq's minimum bid price rule, avoiding delisting after a reverse stock split.

Soligenix, Inc. has entered into a warrant inducement agreement, resulting in potential gross proceeds of $4.2 million and the issuance of new warrants.

Soligenix has enacted a 1-for-16 reverse stock split of its common stock, effective June 5, 2024, to reduce the number of outstanding shares.

Soligenix's 2024 Annual Meeting of Stockholders was adjourned due to insufficient shares represented, and will reconvene on May 30, 2024.

Soligenix, Inc. reports it is in compliance with NASDAQ's minimum shareholders' equity requirement due to a recent debt conversion and public offering.

Soligenix, a biopharmaceutical company, has announced the pricing of a public offering to raise approximately $4.75 million for research, development, and general corporate purposes.

Soligenix has secured agreement from the European Medicines Agency on the design of a confirmatory Phase 3 trial for HyBryte in treating early-stage cutaneous T-cell lymphoma, with patient enrollment expected to begin by the end of 2024.